Davoceticept

N/A

Report date: 2023/06/06 20:00:40

Base Information

Drug NameDavoceticept
Drug Alias NameALPN-202
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsT-cell-specific surface glycoprotein CD28 agonistsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1T-cell-specific surface glycoprotein CD28Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlpine Immune Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlpine Immune Sciences Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphoma

Other Information

ATC CodeN/A
Related LinksN/A